Drug Trial Radar · NCT07172802
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
102
Planned (sponsor's estimate)
Start
Apr 22, 2025
Primary completion
Feb 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- GI Innovation, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Non-small Cell Lung Cancer (NSCLC)
- Head and Neck (HNSCC)
- Pancreatic Cancer
- Renal Cell Carcinoma (RCC)
Interventions
GI-108Drug
Dose level will be escalated from 0.1mg/kg to 1.5 mg/kg and Recommended phase 2 dose (or RP2D) of GI-108 will be administered via IV infusion Q3W upto 2 years (approximately 35 cycles)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting Toxicities (DLTs) (Dose escalation phase)Time frame: Study Day 1, assessed up to DLT period (3 weeks after treatment)
- Incidence and Severity of Immune-Related Adverse Events (irAEs) (Dose escalation phase)Time frame: From Day 1 through study completion (up to ~24 months)
- Objective Response Rate (ORR) according to RECIST version 1.1 (Dose expansion phase)Time frame: Study Day 1, assessed up to approximately 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Yonsei University Health System, Severance Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.